United States Health

Zai Lab (NASDAQ:ZLAB) and argenx (NASDAQ:ARGX) reported that VYVGART Hytrulo met the Phase 3 ALKIVIA primary endpoint with a 15.4-point TIS advantage over placebo at Week 52.

Centene (NYSE:CNC) named Chris Neczypor as its next CFO from January 1, 2027, while reaffirming 2026 adjusted diluted EPS guidance above $4.80.

HUTCHMED (NASDAQ:HCM) reported that ORPATHYS plus TAGRISSO significantly improved progression-free and overall survival versus platinum-based chemotherapy in its 338-patient Phase 3 SAFFRON trial.

Mesoblast (NASDAQ:MESO) completed treatment of 350 patients in its pivotal Phase 3 MSB-DR004 trial of rexlemestrocel-L for chronic low back pain caused by degenerative disc disease.

argenx (NASDAQ:ARGX) reported that subcutaneous VYVGART Hytrulo met the Phase 3 ALKIVIA primary endpoint, producing a 15.4-point greater mean Total Improvement Score than placebo at Week 52.

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said Enhertu significantly improved progression-free survival versus standard first-line treatment for advanced HER2-mutant non-small cell lung cancer.

Tvardi Therapeutics (NASDAQ:TVRD) reported a Q2 2026 net loss of $6.5 million as R&D spending declined to $4 million.

Neumora Therapeutics (NASDAQ:NMRA) reported a Q2 2026 net loss of $43.1 million, narrowing from $52.7 million a year earlier.

Outlook Therapeutics (NASDAQ:OTLK) reported a fiscal Q3 net loss of $20.3 million as it prepares to launch FDA-approved wet AMD treatment LYTENAVA.

TuHURA Biosciences (NASDAQ:HURA) ended Q2 2026 with $1 million in cash as R&D spending rose to $6.6 million amid increased clinical activity.

Lantern Pharma (NASDAQ:LTRN) reported a Q2 operating loss of $3.5 million, down 25%, while emerging LP-300 data showed 8.9-month median progression-free survival in selected patients.

Rein Therapeutics (NASDAQ:RNTX) said its Phase 2 RENEW trial of inhaled LTI-03 has surpassed 25% of planned enrollment of approximately 120 patients.